Labiotech.eu

News and Trends 19 May 2017

Shining new Light on how to control Cell Circuits

Controlling genes with light is a new therapeutic avenue, and researchers from Finland are exploring how it can be used to tinker with the cell’s biochemical circuitry. Their findings could provide a better understanding of degenerative diseases and yield new cancer treatments. Researchers from the Turku Centre for Biotechnology at the University of Turku and Åbo […]

May 19, 2017 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 19 May 2017

MorphoSys’ First Lanthipeptide Completes Phase I Successfully

UPDATE (19/05/2017): MorphoSys has announced the completion of the Phase I study with MOR107, which has proved safe and showed dose-dependent pharmacokinetics. The drug, an agonist of the angiotensin II receptor type 2 (AT2-R), comes from the Dutch Lanthio Pharma and is the first lanthipeptide in MorphoSys’ pipeline. Originally published 21/02/2017 Lanthio Pharma has initiated a […]

May 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 18 May 2017

#Live# Labiotech Hangout: Join our first webcast on anti-aging therapies!

As we grow as a company, our content is growing too! Hang out with us and anti-aging VC managing partner, James Peyer, online next week. Join Now! We can’t wait for an event to produce videos for our readers, and we realized we don’t have to! Next week, we’re trying out a new feature and bringing additional […]

May 18, 2017 - 1 minutemin - By Evelyn Warner

News and Trends 18 May 2017

Spanish Biotech Clears €2.7M Funding Round for its New Stroke Drug

AptaTargets has closed a €2.7M funding round, allowing the biotech to move into the clinic with its first drug candidate for acute ischemic stroke. AptaTargets, located in Madrid, is developing new therapeutic applications based on aptamers. The company is currently focussing on a single lead candidate for the treatment of the acute phase of ischemic […]

May 18, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 18 May 2017

Heptares receives €4.5M Milestone for New Migraine Drug Candidate

The UK biotech attacking notoriously evasive GPCRs has discovered a small molecule that could be used to treat migraine headaches. Heptares, owned by Sosei and based just outside London, will take home €4.5M ($5M) from Teva for discovering a drug candidate for migraine treatment. The small molecule is an calcitonin gene-related peptide (CGRP) agonist that could relieve patients […]

May 18, 2017 - 1 minutemin - By Evelyn Warner

abcam axiomx acquisition milestone antibody

More News! 18 May 2017

Abcam Makes Final Payment in the Acquisition of an US Antibody Biotech

Abcam has paid US-based AxioMx a final €4.5M milestone based on performance, completing an acquisition that totals €36.4M. Giant antibody maker Abcam, founded by star biotech entrepreneur Jonathan Milner and based in Cambridge, has announced it made the last payment part of its acquisition deal with AxioMx. The deal was initiated in November 2015 with a […]

May 18, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Aurora tt Italy technology transfer biotech fund

News and Trends 18 May 2017

Italy is Getting its First-Ever Early Stage Biotech Fund for Tech Transfer

AurorA-TT is making plans to raise €50M for what will be the first fund dedicated to investing in tech transfer within the Italian biotech ecosystem. AurorA-TT is a newborn company in Milan with the goal of promoting technology transfer in Italy. To do so, the plan is to raise a €50M fund dedicated to biotech. “There’s […]

May 18, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 May 2017

Danish Biotech Targeting Ion Channels Completes Private Placement

The biotech company Saniona has announced the issue of new shares to Swedish and international investors, raising a total of €3.6M. Saniona, a Danish biotech listed on the Nasdaq First North Premier, just completed a private placement that raised €3.6M (SEK 35M) before issue costs. The funds are intended to provide the company with more flexibility […]

May 17, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 17 May 2017

A Spanish Biosimilar of Amgen’s Blockbuster gets Ready for EU Approval

Cinfa Biotech announced trial results for a biosimilar of Amgen’s Neulasta, a multi-billion blockbuster to treat chemotherapy-induced neutropenia. Cinfa Biotech is a Spanish company specialized in developing biosimilars. The biotech has announced positive results from the second clinical trial evaluating a biosimilar version of Neulasta (pegfilgrastim), Amgen’s second top-selling drug. It brought the big pharma €4.2Bn in […]

May 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 May 2017

Way to Success: What Role does Company Culture Play in Biotech?

You’ve surely heard how great company culture is the key to the success of tech giants Google and Facebook. Does it also apply to biotech companies? Company culture is what drives employees to give their best every day for a cause they believe in. It’s what makes the best stay loyal to a firm over […]

May 17, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

Noxxon Merck checkpoint inhibitor combination

News and Trends 16 May 2017

Berlin Biotech Advances its Cancer Drug in a New Trial with Keytruda

Noxxon Pharma has teamed up with the NCT in Heidelberg to conduct a Phase I/II trial combining its lead NOX-A12 with checkpoint inhibitor Keytruda. Based in Berlin, Noxxon is yet another biotech looking to bolster the success of checkpoint inhibitors by combining them with its ‘next-generation’ immuno-oncology candidates. The company partnered up with Merck & Co. […]

May 16, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 15 May 2017

German Biotech Clears Phase I with New Gene Therapy for Glaucoma

Isarna Therapeutics showed off positive Phase I data for its lead compound ISTH0036 in patients with Glaucoma at the ARVO meeting last week. Isarna Therapeutics from Munich is developing TGF-β specific antisense RNA therapeutics to treat ophthalmic and fibrotic diseases and cancer. Now the company has cleared its first Phase I trial for its lead candidate ISTH0036 in […]

May 15, 2017 - 2 minutesmins - By Melanie De Almeida

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Shining new Light on how to control Cell Circuits

MorphoSys’ First Lanthipeptide Completes Phase I Successfully

#Live# Labiotech Hangout: Join our first webcast on anti-aging therapies!

Spanish Biotech Clears €2.7M Funding Round for its New Stroke Drug

Heptares receives €4.5M Milestone for New Migraine Drug Candidate

Abcam Makes Final Payment in the Acquisition of an US Antibody Biotech

Italy is Getting its First-Ever Early Stage Biotech Fund for Tech Transfer

Danish Biotech Targeting Ion Channels Completes Private Placement

A Spanish Biosimilar of Amgen’s Blockbuster gets Ready for EU Approval

Way to Success: What Role does Company Culture Play in Biotech?

Berlin Biotech Advances its Cancer Drug in a New Trial with Keytruda

German Biotech Clears Phase I with New Gene Therapy for Glaucoma

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!